Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06257810
Other study ID # E0545
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date June 1, 2023
Est. completion date October 24, 2023

Study information

Verified date February 2024
Source BioMérieux
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The differential and systematic diagnosis of malaria, dengue and chikungunya in patients with fever (≥38.5°C) of undetermined etiology would allow the identification of infection by these pathogens and thus limit the inappropriate use of antibiotics (discontinuation or non-initiation) and optimize the clinical management and prognosis of patients.


Description:

The research hypotheses are as follows: - Systematic diagnosis of malaria, dengue and chikungunya using diagnostic tests would improve the clinical management of patients with fever of undetermined etiology and reduce the misuse of antibiotics (discontinuation or non-initiation) and associated resistance. - Improved management is associated with a reduction in the use of hospital resources, professional inactivity and an improvement in the quality of life and satisfaction of patients.


Recruitment information / eligibility

Status Completed
Enrollment 804
Est. completion date October 24, 2023
Est. primary completion date June 7, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Subjects aged = 18 years - Patient with fever (=38.5°C) and at least two of the following symptoms in the last 10 days: - Severe headache - Retro-orbital pain - Muscle and joint pain - Nausea - Vomiting - Adenopathy - Rash - Abdominal pain - Asthenia - Spontaneous bleeding (purpura, epistaxis, haematemesis, etc) - Willingness and ability to provide two 4 mL blood samples - Willingness to provide one drop of blood per capillary sample - Informed and signed consent Exclusion Criteria: - Subjects aged < 18 years - Pregnant women - Breastfeeding women - Patient's refusal to participate in the study

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
VIDAS® Dengue Antigen NS1, VIDAS® Anti-Dengue IgM, VIDAS® Anti-Dengue IgG, VIDAS® Anti-Chikungunya IgM and VIDAS® Anti-Chikungunya IgG
For patients managed in an "intervention site", a diagnostic test for dengue and chikungunya using VIDAS® as well as a screening test for malaria will be carried out. An awareness campaign on the use of VIDAS® diagnostic tests will be implemented as well. The diagnosis will be based on the patient's clinical symptoms, the biological results of the VIDAS® tests for dengue and chikungunya, as well as the results of the tests for malaria.
Other:
Standard of care practices
For patients managed in a "control site", the standard of care practices will be applied in the case of a febrile condition of undetermined etiology. This includes clinical diagnosis and, where appropriate, the use of routinely available diagnostic tests. At the end of the study, the collected samples will be tested using VIDAS® differential diagnosis tests to estimate the number of cases of dengue and chikungunya that have not been correctly diagnosed.

Locations

Country Name City State
Burkina Faso Institut de Recherche en Sciences de la Santé Ouagadougou
Côte D'Ivoire CHU Cocody Abidjan Cocody
Côte D'Ivoire CHU Treichville Abidjan Treichville

Sponsors (1)

Lead Sponsor Collaborator
BioMérieux

Countries where clinical trial is conducted

Burkina Faso,  Côte D'Ivoire, 

Outcome

Type Measure Description Time frame Safety issue
Other Prevalence of dengue, chikungunya and malaria To determine the prevalence of dengue, chikungunya and malaria in patients with fever (=38.5°C) of undetermined etiology Inclusion, after lab results (an average of one day)
Other Clinical situations associated with inappropriate antibiotic prescription Number of clinical situations associated with inappropriate antibiotic prescription, including suggestive signs of bacterial infection or severe sepsis such as neurological, cardio-circulatory failure, coma or purpura fulminans Inclusion and Day 7
Other Rate of antibiotic prescription To estimate the impact of differential diagnosis testing on the rate of antibiotic prescription in patients with dengue and/or chikungunya Up to 7 days
Primary Rate of antibiotic prescription Rate of antibiotic prescription (discontinuation or non-initiation). Inclusion and Day 7
Secondary Consumption of hospital resources Number of days in hospital. Day 7
Secondary Consumption of hospital resources Number of hospital visits within 7 days. Day 7
Secondary Patient satisfaction Patient satisfaction with the health care (measured on a scale of 1 (worse) to 5 (better)). Inclusion and Day 7
Secondary Patient's quality of life Percentage on patient's quality of life (1 (worse) to 100 (better)) + EQ-5D questionnaire. Inclusion and Day 7
Secondary Patient's loss of productivity Questionnaire on number of working day lost. Inclusion and Day 7
See also
  Status Clinical Trial Phase
Completed NCT04601714 - Baseline Cohort Malaria Morbidity Study
Withdrawn NCT04020653 - A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria Phase 2
Terminated NCT04368910 - Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria Phase 3
Completed NCT03641339 - Defining Skin Immunity of a Bite of Key Insect Vectors in Humans N/A
Completed NCT02544048 - Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
Completed NCT00527163 - Role of Nitric Oxide in Malaria
Not yet recruiting NCT05934318 - L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE) N/A
Active, not recruiting NCT04704674 - Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
Completed NCT03276962 - Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age Phase 2
Completed NCT04966871 - Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults Phase 1
Completed NCT00289185 - Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants Phase 2
Recruiting NCT03937817 - Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
Active, not recruiting NCT06153862 - Africa Ready Malaria Screening N/A
Completed NCT04545905 - Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
Recruiting NCT06278181 - Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
Completed NCT02909712 - Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania Phase 2
Withdrawn NCT02793414 - Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
Withdrawn NCT02793388 - A Trial on Supervised Primaquine Use in Ethiopia Phase 4
Completed NCT02793622 - Prevention of Malaria in HIV-uninfected Pregnant Women and Infants Phase 3
Completed NCT02605720 - Cardiac Safety of Repeated Doses of Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns Phase 3